Life Sciences, Diagnostics Drive Danaher Q2 Revenues Up 4 Percent
Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.
Life Sciences, Diagnostics Drive Danaher Q4 Revenues Up 11 Percent
In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year.
Danaher Initiates 2018 Guidance
The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35.